We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

TachoSil Paediatric Liver Trial (TC-019-IN)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00365248
First Posted: August 17, 2006
Last Update Posted: May 7, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Nycomed
  Purpose
The overall objective is to assess the haemostatic efficacy and safety of TachoSil for control of local bleeding in paediatric patients undergoing surgical resection of the liver with our without segmental liver transplantation.

Condition Intervention Phase
Liver Diseases Drug: Fibrinogen human (TachoSil) Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multi-centre Phase III-b Study of TachoSil in Paediatric Patients Scheduled for Resection of the Liver With or Without Segmental Liver Transplantation.

Resource links provided by NLM:


Further study details as provided by Nycomed:

Primary Outcome Measures:
  • The primary objective is to collect data on efficacy, i.e. intra-operative haemostasis, and safety of TachoSil ® as treatment to control local bleeding in children undergoing surgical resection of the liver with or without segmental transplantation. [ Time Frame: 7½ months ]

Enrollment: 16
Study Start Date: October 2005
Study Completion Date: May 2008
Intervention Details:
    Drug: Fibrinogen human (TachoSil)
    Resection of the liver with or without segmental liver transplantation
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 6 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Has the parent(s)/legal guardian given informed consent according to local requirements before any trial related activities?
  2. Is the child above 4 weeks and below 6 years of age?
  3. Has at least segmental resection (anatomical/non-anatomical) of the liver and primary haemostatic treatment been performed? or Has resection of the liver and placement of a segmental liver graft and primary haemostatic treatment been performed?
  4. Is only minor, i.e. oozing, or moderate haemorrhage persisting after primary surgical haemostatic procedures of the major vessels (no pulsating arterial haemorrhage and/or major venous bleeding)?

All inclusion criteria must be answered "yes" for a child to participate in the study.

Exclusion criteria:

  1. Was the child retransplanted or had liver transplantation in combination with other organs?
  2. Was there anamnestic or laboratory evidence of congenital coagulation disorders including Haemophilia A or B and von Willebrand disease?
  3. Has the child a history of allergic reactions after application of human fibrinogen, human thrombin and/or collagen of any origin?
  4. Has the child fulminant hepatic failure, portal vein thrombosis or anamnestic or clinical evidence of cirrhotic condition of the liver, including cirrhosis due to genetic deficiency of a1 - Antitrypsin?
  5. Did the child undergo an emergency operation?
  6. Does the child participate in another clinical trial during the intra-operative phase?
  7. Has any serious surgical complication occurred?
  8. Has any fibrin glue haemostatic (including TachoSil ® ) been used on the target wound before the planned application of TachoSil ® ? To participate in the study all exclusion criteria must be answered "No" for a child having segmental resection. For a child having total hepatectomy and placement of a segmental liver transplant criteria 4 and 5 can be answered "Yes".
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00365248


Locations
Denmark
Nycomed
Roskilde, Denmark, 4000
Sponsors and Collaborators
Nycomed
Investigators
Study Chair: Clinical Trial Operations Headquaters
  More Information

Responsible Party: Nycomed
ClinicalTrials.gov Identifier: NCT00365248     History of Changes
Other Study ID Numbers: TC-019-IN
2004-005028-42
First Submitted: August 16, 2006
First Posted: August 17, 2006
Last Update Posted: May 7, 2012
Last Verified: July 2008

Keywords provided by Nycomed:
Surgical resection of the liver with or without segmental transplantation

Additional relevant MeSH terms:
Liver Diseases
Digestive System Diseases